Interim results from an international, open-label study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease: efficacy results by country
نویسندگان
چکیده
Interim results from an international, open-label study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease: efficacy results by country P. Odin1,2, A.J. Espay3, A.D. Vanagunas4, R.A. Hauser5, H.H. Fernandez6, D.G. Standaert7, W.Z. Robieson8, Y. Pritchett8, K.L. Widnell8, K. Chatamra8, J. Benesh8, R.A. Lenz8 1Klinikum-Bremerhaven, Bremerhaven, Germany, 2Skane University Hospital, Lund, Sweden, 3University of Cincinnati Academic Health Center, Cincinnati, OH, 4Northwestern University, Chicago, IL, 5University of South Florida, Tampa, FL, 6Cleveland Clinic, Cleveland, OH, 7University of Alabama at Birmingham, Birmingham, AL, 8Abbott, Abbott Park, IL, USA
منابع مشابه
Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease
Objectives Levodopa-carbidopa intestinal gel (LCIG) was developed to reduce motor complications in Parkinson's disease (PD) caused by pulsatile levodopa plasma concentrations following oral levodopa administration. Dyskinesia and 'wearing off' symptoms can vary between Asian and Caucasian patients with PD, thus highlighting the importance of assessing the effectiveness of LCIG in an Asian popul...
متن کاملEffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
OBJECTIVE The purpose of this study was to assess the effect of levodopa-carbidopa intestinal gel (carbidopa-levodopa enteral suspension) in advanced Parkinson's disease patients with troublesome dyskinesia. METHODS Post hoc analyses of patient data from a 12-week, randomized, double-blind study and a 54-week open-label study were performed. Efficacy was assessed in the subgroup of patients d...
متن کاملLevodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
In a double-blind, double-dummy, double-titration Phase 3 trial in advanced Parkinson's disease (PD) patients, the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) infusion were characterized relative to immediate-release oral levodopa-carbidopa (LC-oral) treatment. We present in this report the comparative pharmacokinetic profiles of LCIG and LC-oral from this pivotal study. The...
متن کاملJejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
BACKGROUND AND OBJECTIVE Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson's disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa-carbidopa intestinal gel (LCIG) provides individualized continuous levodopa-carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and e...
متن کاملUse of advanced therapies for Parkinson's disease in Norway.
BACKGROUND Many patients with Parkinson’s disease with severe motor fluctuations benefit from advanced therapies – either deep brain stimulation or continuous infusion therapy with levodopa-carbidopa intestinal gel or apomorphine. In Norway, deep brain stimulation is provided as a shared national or multi-regional service. The treatment is currently available at Oslo University Hospital and St....
متن کامل